Biotech is advancing faster than ever, but persistent challenges in clinical trial recruitment, representative data, patient access, and trust continue to slow the path from scientific breakthrough to real-world impact.
This panel discussion will explore why traditional approaches to community engagement often begin too late and what it would look like to build trusted community infrastructure before recruitment or commercialization begins. Using Roxbury as a real-world case study, panelists will examine how biotech, healthcare, technology, government, and communities can create stronger pathways to research participation, better data, broader adoption, and ultimately better outcomes.
The question for biotech leaders: What if community trust were treated with the same strategic importance as the other infrastructure required to bring innovation to market?
Featuring
Biotech is advancing faster than ever, but persistent challenges in clinical trial recruitment, representative data, patient access, and trust continue to slow the path from scientific breakthrough to real-world impact.
This panel discussion will explore why traditional approaches to community engagement often begin too late and what it would look like to build trusted community infrastructure before recruitment or commercialization begins. Using Roxbury as a real-world case study, panelists will examine how biotech, healthcare, technology, government, and communities can create stronger pathways to research participation, better data, broader adoption, and ultimately better outcomes.
The question for biotech leaders: What if community trust were treated with the same strategic importance as the other infrastructure required to bring innovation to market?
Featuring